Equitec Proprietary Markets, LLC Pharma Cyte Biotech, Inc. Transaction History
Equitec Proprietary Markets, LLC
- $92.9 Million
- Q3 2024
A detailed history of Equitec Proprietary Markets, LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Equitec Proprietary Markets, LLC holds 82,727 shares of PMCB stock, worth $132,363. This represents 0.17% of its overall portfolio holdings.
Number of Shares
82,727
Previous 82,727
-0.0%
Holding current value
$132,363
Previous $162,000
2.47%
% of portfolio
0.17%
Previous 0.18%
Shares
6 transactions
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$334,8250.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$307,8190.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$269,1200.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$147,3397.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.7KShares$79,5200.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $33.2M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...